COPENHAGEN, Denmark, Sept. 14 /PRNewswire-FirstCall/ -- Genmab A/S (CSE: GEN - News) announced today it has initiated a Phase III pivotal study with HuMax- EGFr(TM) (zalutumumab) to treat patients with head and neck cancer that is considered incurable with standard treatment.
